An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers

Nature Genetics

Volumn 45, Issue 9, 2013, Pages 970-976

  Roberts, Steven A ^a   Lawrence, Michael S ^b   Klimczak, Leszek J ^a   Grimm, Sara A ^a   Fargo, David ^a   Stojanov, Petar ^b   Kiezun, Adam ^b   Kryukov, Gregory V ^b,c   Carter, Scott L ^b   Saksena, Gordon ^b   Harris, Shawn ^d   Shah, Ruchir R ^d   Resnick, Michael A ^a   Getz, Gad ^b,e,f   Gordenin, Dmitry A ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d SRA International Inc   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^f MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3F; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CYTIDINE DEAMINASE; MESSENGER RNA; TUMOR ANTIGEN; URACIL DNA GLYCOSIDASE; APOLIPOPROTEIN B MRNA EDITING ENZYME; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BLADDER CANCER; BREAST CANCER; CHROMOSOME REARRANGEMENT; COPY NUMBER VARIATION; DNA STRAND; EXOME; HEAD AND NECK CANCER; HUMAN; HUMAN GENOME; LUNG CANCER; MISSENSE MUTATION; MUTAGENESIS; NEOPLASM; NONSENSE MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA SEQUENCE; UTERINE CERVIX CANCER; BREAST TUMOR; CELL TRANSFORMATION; FEMALE; GENETICS; GENOMICS; MALE; MUTATION;

BREAST NEOPLASMS; CELL TRANSFORMATION, NEOPLASTIC; CYTIDINE DEAMINASE; EXOME; FEMALE; GENOME, HUMAN; GENOMICS; HUMANS; MALE; MUTAGENESIS; MUTATION; NEOPLASMS; RECEPTOR, ERBB-2; RNA, MESSENGER;

EID: 84883432724     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng.2702     Document Type: Article

References (51)

1. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
2. Loeb, L.A. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res. 51, 3075-3079 (1991).
3. Luch, A. Nature and nurture - lessons from chemical carcinogenesis. Nat. Rev. Cancer 5, 113-125 (2005).
4. Conticello, S.G. Creative deaminases, self-inflicted damage, and genome evolution. Ann. NY Acad. Sci. 1267, 79-85 (2012).
5. Pavri, R. & Nussenzweig, M.C. AID targeting in antibody diversity. Adv. Immunol. 110, 1-26 (2011).
6. Smith, H.C., Bennett, R.P., Kizilyer, A., McDougall, W.M. & Prohaska, K.M. Functions and regulation of the APOBEC family of proteins. Semin. Cell Dev. Biol. 23, 258-268 (2012).
7. Suspène, R. et al. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway for DNA catabolism. Proc. Natl. Acad. Sci. USA 108, 4858-4863 (2011).
8. Shinohara, M. et al. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci. Rep. 2, 806 (2012).
9. Burns, M.B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366-370 (2013).
10. Stephens, P. et al. A screen of the complete protein kinase gene family identifies diverse patterns of somatic mutations in human breast cancer. Nat. Genet. 37, 590-592 (2005).
11. Beale, R.C. et al. Comparison of the differential context-dependence of DNA deamination by APOBEC enzymes: correlation with mutation spectra in vivo. J. Mol. Biol. 337, 585-596 (2004).
12. Nik-Zainal, S. et al. Mutational processes molding the genomes of 21 breast cancers. Cell 149, 979-993 (2012).
13. Roberts, S.A. et al. Clustered mutations in yeast and in human cancers can arise from damaged long single-strand DNA regions. Mol. Cell 46, 424-435 (2012).
14. Drier, Y. et al. Somatic rearrangements across cancer reveal classes of samples with distinct patterns of DNA breakage and rearrangement-induced hypermutability. Genome Res. 23, 228-235 (2013).
15. Gibbs, P.E. & Lawrence, C.W. Novel mutagenic properties of abasic sites in Saccharomyces cerevisiae. J. Mol. Biol. 251, 229-236 (1995).
16. Simonelli, V., Narciso, L., Dogliotti, E. & Fortini, P. Base excision repair intermediates are mutagenic in mammalian cells. Nucleic Acids Res. 33, 4404-4411 (2005).
17. Chan, K. et al. Base damage within single-strand DNA underlies in vivo hypermutability induced by a ubiquitous environmental agent. PLoS Genet. 8, e1003149 (2012).
18. Senavirathne, G. et al. Single-stranded DNA scanning and deamination by APOBEC3G cytidine deaminase at single molecule resolution. J. Biol. Chem. 287, 15826-15835 (2012).
19. Chelico, L., Pham, P. & Goodman, M.F. Mechanisms of APOBEC3G-catalyzed processive deamination of deoxycytidine on single-stranded DNA. Nat. Struct. Mol. Biol. 16, 454-455, author reply 455-456 (2009).
20. Barbieri, C.E. et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 44, 685-689 (2012).
21. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
22. Bass, A.J. et al. Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat. Genet. 43, 964-968 (2011).
23. Shammas, M.A. et al. Dysfunctional homologous recombination mediates genomic instability and progression in myeloma. Blood 113, 2290-2297 (2009).
24. Liu, P., Carvalho, C.M., Hastings, P.J. & Lupski, J.R. Mechanisms for recurrent and complex human genomic rearrangements. Curr. Opin. Genet. Dev. 22, 211-220 (2012).
25. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
26. Parker, J.S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
27. Landry, S., Narvaiza, I., Linfesty, D.C. & Weitzman, M.D. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep. 12, 444-450 (2011).
28. Carter, H. et al. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 69, 6660-6667 (2009).
29. Douville, C. et al. CRAVAT: Cancer-Related Analysis of VAriants Toolkit. Bioinformatics 29, 647-648 (2013).
30. Forbes, S.A. et al. The Catalogue of Somatic Mutations in Cancer (COSMIC). Curr Protoc. Hum. Genet. Chapter 10, Unit 10.11 (2008).
31. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004).
32. Lampson, B.L. et al. Rare codons regulate KRas oncogenesis. Curr. Biol. 23, 70-75 (2012).
33. Schumacher, A.J., Nissley, D.V. & Harris, R.S. APOBEC3G hypermutates genomic DNA and inhibits Ty1 retrotransposition in yeast. Proc. Natl. Acad. Sci. USA 102, 9854-9859 (2005).
34. Einav, U. et al. Gene expression analysis reveals a strong signature of an interferon-induced pathway in childhood lymphoblastic leukemia as well as in breast and ovarian cancer. Oncogene 24, 6367-6375 (2005).
35. Refsland, E.W. et al. Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38, 4274-4284 (2010).
36. Menendez, D., Shatz, M. & Resnick, M.A. Interactions between the tumor suppressor p53 and immune responses. Curr. Opin. Oncol. 25, 85-92 (2013).
37. Zhou, L. et al. Activation of toll-like receptor-3 induces interferon-λ expression in human neuronal cells. Neuroscience 159, 629-637 (2009).
38. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr. Eval. Carcinog. Risks Hum. 100, 1-441 (2012).
39. Lee, E. et al. Landscape of somatic retrotransposition in human cancers. Science 337, 967-971 (2012).
40. Lopes, M., Foiani, M. & Sogo, J.M. Multiple mechanisms control chromosome integrity after replication fork uncoupling and restart at irreparable UV lesions. Mol. Cell 21, 15-27 (2006).
41. Pagès, V. & Fuchs, R.P. Uncoupling of leading- and lagging-strand DNA replication during lesion bypass in vivo. Science 300, 1300-1303 (2003).
42. Bouwman, P. et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat. Struct. Mol. Biol. 17, 688-695 (2010).
43. Bunting, S.F. et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 141, 243-254 (2010).
44. Bando, M. et al. Csm3, Tof1, and Mrc1 form a heterotrimeric mediator complex that associates with DNA replication forks. J. Biol. Chem. 284, 34355-34365 (2009).
45. Katou, Y. et al. S-phase checkpoint proteins Tof1 and Mrc1 form a stable replication-pausing complex. Nature 424, 1078-1083 (2003).
46. Yates, L.R. & Campbell, P.J. Evolution of the cancer genome. Nat. Rev. Genet. 13, 795-806 (2012).
47. Chapman, M.A. et al. Initial genome sequencing and analysis of multiple myeloma. Nature 471, 467-472 (2011).
48. Berger, M.F. et al. The genomic complexity of primary human prostate cancer. Nature 470, 214-220 (2011).
49. Harfe, B.D. & Jinks-Robertson, S. DNA polymerase ζ introduces multiple mutations when bypassing spontaneous DNA damage in Saccharomyces cerevisiae. Mol. Cell 6, 1491-1499 (2000).
50. Sakamoto, A.N. et al. Mutator alleles of yeast DNA polymerase ζ. DNA Repair (Amst.) 6, 1829-1838 (2007).
51. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. R. Stat. Soc., B 57, 289-300 (1995).